Axsome Therapeutics, Inc.

A week after announcing results for solriamfetol in attention deficit hyperactivity disorder (ADHD) that left some analysts questioning its market differentiation, Axsome Therapeutics has released top

Axsome Therapeutics scored a win with the Phase III FOCUS trial of solriamfetol in attention deficient hyperactivity disorder (ADHD) among adults, which supports further development of the drug but ha

Fresh off its approval from the US Food and Drug Administration, Axsome Therapeutics’ migraine drug Symbravo (meloxicam and rizatriptan) stands to potentially strengthen its position in a crowded mark

Axsome Therapeutics has again demonstrated the strength of its intellectual property portfolio, shaking hands with Teva on a settlement in patent-litigation proceedings that will keep the Israeli firm